Dr Reddy's Laboratories Q3 Results: Pharma firm beat research estimates; PAT, revenue jump in December quarter
The company's consolidated revenue from operations also saw a rise of 7.05 per cent as it also beat analysts' estimates to rise to Rs 7237 crore in Q3 from Rs 6760 crore in the same quarter last fiscal. The revenue was above the research estimate of Rs 6914 crore.
)
Dr Reddy's Laboratories Q3 Results: One of India's leading pharmaceuticals companies, Dr Reddy's Laboratories, announced it December quarter results on Tuesday (January 30, 2024), reporting a 10.74 per cent jump in its consolidated PAT YoY.
The company's consolidated profit afer tax (PAT) beat Zee Business research estimates of Rs 1310 crore, as it rose to Rs 1381 crore in the December quarter from Rs 1247 crore Year-on-Year (YoY).
The company's consolidated revenue from operations saw a jump of 7.05 per cent as it rose to Rs 7237 crore in Q3 from Rs 6760 crore in the same quarter last fiscal. The revenue was above the research estimates of Rs 6914 crore.
Dr Reddy's Laboratories reported a 7.36 per cent jump in its EBIDTA to Rs 2110.70 crore from Rs 1966 crore YoY.
The margins were higher by 29.3 per cent in the third quarter from 29 per cent in the year-ago period.
Dr Reddy's Share Price
The stock of the company ended flat at Rs 5845.75 on Tuesday.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
04:34 PM IST
Dr Reddy’s Lab Q3 Results Preview: Pharma firm expected to clock sluggish December quarter results
Dr Reddy's Q3 results: Company reports over 75% YoY jump in consolidated net profit, revenues up 27%
Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore
Pharma Q3: FDA inspection, US pricing market key